Anaplastic Large Cell Lymphoma (systemic) · line 2 · Brentuximab vedotin maintenance post-ASCT for high-risk systemic ALCL (AETHERA-style, 16 cycles)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-BRENTUXIMAB-MAINTENANCE-ALCL |
| ID | IND-ALCL-MAINTENANCE-BV-POST-ASCT |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-ALCL |
| Sources | SRC-ECHELON-2-HORWITZ-2019 SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB. Extrapolated from AETHERA cHL paradigm; off-label in this setting in UA. Funding via fundraising typical. ALK- ALCL with high-risk features is the strongest population for benefit.
Used By
Algorithms
ALGO-ALCL-2L- ALGO-ALCL-2L